SMSbiotech, a clinical-stage regenerative medicine company focused on developing novel cell-based therapies, announced the appointment of Joe Kiani as Chairman of its Board of Directors. Kiani, an early supporter of the company, brings extensive healthcare leadership experience and strategic expertise that will support SMSbiotech’s next stage of clinical and commercial growth.
Dr. Abdulkader Rahmo, President of SMSbiotech, said that Kiani’s experience and strategic guidance will be invaluable as the company advances in regenerative cell therapy and positions itself at the forefront of innovation in the field. Kiani will collaborate closely with the Board and executive team to shape corporate strategy, prioritize clinical development initiatives, and drive long-term value creation. His appointment comes at a pivotal moment as SMSbiotech builds on clinical momentum and prepares for expanded regulatory and commercialization efforts.
Health Technology Insights: Corus Orthodontists Secures C$20 Million Equity Investment
“I am honored to take on this role at a time when the science has the potential to bring real hope to patients,” said Joe Kiani, Chairman of SMSbiotech. “What excites me most is not just the promise of regenerative medicine, but the opportunity to improve quality of life for individuals living with chronic and degenerative conditions. These advancements have the potential to move beyond symptom management and toward restoring function, independence, and dignity for patients around the world.”
Over the past year, SMSbiotech has made significant progress across its regenerative medicine platform. The company completed the first cohort in a Phase 1b clinical trial for chronic obstructive pulmonary disease, demonstrating safety and early signs of efficacy. Concurrently, SMSbiotech initiated multiple human pilot studies across different indications, reporting promising biological responses. Additional preclinical work highlighted positive interactions between SMS cells and other critical cell types involved in tissue regeneration, expanding the therapeutic potential of the platform. The company also established a phase-appropriate cGMP biomanufacturing facility to support ongoing and future clinical programs.
Looking ahead, SMSbiotech has set ambitious objectives for 2026. The company plans to complete the Phase 1b COPD trial in Australia, secure Investigational New Drug approval in the United States, and advance into Phase 2 clinical development. SMSbiotech also aims to finish a Phase 1 study in osteoarthritis while exploring additional indications for its proprietary SMS cell technology. In parallel, the company intends to generate early global revenue by engaging a dedicated sales force to support its innovative cell therapy platform.
Joe Kiani, founder of Masimo and its Chairman and CEO for nearly 36 years, is a recognized healthcare innovator with a proven record of scaling mission-driven companies and bringing technologies to market that improve patient outcomes. In his role as Chairman of SMSbiotech, he will guide the company as it moves from early clinical development to broader clinical validation and commercialization, helping advance the promise of regenerative medicine.
Health Technology Insights: SEQSTER Expands Partnership with Praxis Precision Medicines
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
